STAA May 2024 50.000 call
| Previous close | 1.0000 |
| Open | 0.9000 |
| Bid | 0.8500 |
| Ask | 1.0000 |
| Strike | 50.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.8500 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 405 |
Simply Wall St.STAAR Surgical Company's (NASDAQ:STAA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
STAAR Surgical (NASDAQ:STAA) has had a great run on the share market with its stock up by a significant 64% over the...
Business WireSTAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
LAKE FOREST, Calif., May 01, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.
Business WireSTAAR Surgical to Report First Quarter Results on May 7, 2024
LAKE FOREST, Calif., April 29, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
